LLY

818.58

+0.92%↑

JNJ

156.9

+0.22%↑

ABBV

190.58

-0.85%↓

NVO

79.74

-1.64%↓

UNH

313.25

-1.52%↓

LLY

818.58

+0.92%↑

JNJ

156.9

+0.22%↑

ABBV

190.58

-0.85%↓

NVO

79.74

-1.64%↓

UNH

313.25

-1.52%↓

LLY

818.58

+0.92%↑

JNJ

156.9

+0.22%↑

ABBV

190.58

-0.85%↓

NVO

79.74

-1.64%↓

UNH

313.25

-1.52%↓

LLY

818.58

+0.92%↑

JNJ

156.9

+0.22%↑

ABBV

190.58

-0.85%↓

NVO

79.74

-1.64%↓

UNH

313.25

-1.52%↓

LLY

818.58

+0.92%↑

JNJ

156.9

+0.22%↑

ABBV

190.58

-0.85%↓

NVO

79.74

-1.64%↓

UNH

313.25

-1.52%↓

Search

Arbutus Biopharma Corp

Cerrado

3.52 -1.4

Resumen

Variación precio

24h

Actual

Mínimo

3.48

Máximo

3.57

Métricas clave

By Trading Economics

Ingresos

-12M

-25M

Ventas

190K

1.8M

BPA

-0.182

Margen de beneficios

-1,390.363

Empleados

44

EBITDA

-12M

-24M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 Meses

+41.64% upside

Dividendos

By Dow Jones

Próximas Ganancias

31 jul 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

31M

672M

Apertura anterior

4.92

Cierre anterior

3.52

Puntuación técnica

By Trading Central

Confianza

Weak Bearish Evidence

Arbutus Biopharma Corp Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

13 jun 2025, 22:33 UTC

Adquisiciones, fusiones, absorciones

Millicom to Acquire Telefonica Ecuador for $380 Million

13 jun 2025, 23:50 UTC

Adquisiciones, fusiones, absorciones

Trump and Nippon Steel Reach National-Security Agreement on U.S. Steel Deal -- 2nd Update

13 jun 2025, 23:20 UTC

Adquisiciones, fusiones, absorciones

Trump and Nippon Steel Reach National-Security Agreement on U.S. Steel Deal -- Update

13 jun 2025, 23:09 UTC

Adquisiciones, fusiones, absorciones

Trump, Nippon Steel Reach National-Security Agreement on U.S. Steel Deal -- WSJ

13 jun 2025, 23:03 UTC

Adquisiciones, fusiones, absorciones

Trump, Nippon Steel Reach National-Security Agreement on U.S. Steel Deal --WSJ

13 jun 2025, 22:18 UTC

Adquisiciones, fusiones, absorciones

Millicom to Acquire Telefonica Ecuador for $380M

13 jun 2025, 22:04 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Better Data Facilitate Investments In Oil Patch -- Market Talk

13 jun 2025, 21:42 UTC

Adquisiciones, fusiones, absorciones

Anne Wojcicki Wins Bidding for 23andMe -- 2nd Update

13 jun 2025, 21:35 UTC

Adquisiciones, fusiones, absorciones

Bunge: Outside Date Extended to July 3

13 jun 2025, 21:35 UTC

Adquisiciones, fusiones, absorciones

Bunge: Subject to Satisfaction of Remaining Conditions, Bunge and Sellers Expect to Complete Transaction July 2

13 jun 2025, 21:34 UTC

Adquisiciones, fusiones, absorciones

Bunge Gets Mexico Approval for Viterra Deal

13 jun 2025, 21:32 UTC

Adquisiciones, fusiones, absorciones

Bunge Gets China Approval for Viterra Deal

13 jun 2025, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

13 jun 2025, 20:45 UTC

Adquisiciones, fusiones, absorciones

23andMe: TTAM Makes Binding Commitments for Additional Consumer Protections and Privacy Safeguards

13 jun 2025, 20:34 UTC

Adquisiciones, fusiones, absorciones

Anne Wojcicki Wins Bidding for 23andMe -- Update

13 jun 2025, 20:14 UTC

Adquisiciones, fusiones, absorciones

Nonprofit Controlled By 23andMe Co-Founder Anne Wojcicki Would Buy the DNA-Testing Company for $305 Million -- WSJ

13 jun 2025, 20:14 UTC

Adquisiciones, fusiones, absorciones

Anne Wojcicki Wins Bidding for 23andMe -- WSJ

13 jun 2025, 20:14 UTC

Adquisiciones, fusiones, absorciones

Regeneron Walks Away From 23andMe Acquisition After Wojcicki's Higher Bid -- WSJ

13 jun 2025, 19:30 UTC

Charlas de Mercado

U.S. Natural Gas Futures Post Moderate Gains -- Market Talk

13 jun 2025, 19:12 UTC

Charlas de Mercado

Oil Futures Jump As Israel Strikes Iranian Targets -- Market Talk

13 jun 2025, 19:04 UTC

Charlas de Mercado

Canada Military Spending Hike to Lift Long-Term Yields -- Market Talk

13 jun 2025, 18:54 UTC

Charlas de Mercado

Correction to Gold Settles Market Talk

13 jun 2025, 18:01 UTC

Charlas de Mercado

Gold Settles at Record High -- Market Talk

13 jun 2025, 17:40 UTC

Charlas de Mercado

U.S. Oil Rig Count Falls By 3 to 439 -- Market Talk

13 jun 2025, 17:21 UTC

Charlas de Mercado

Dollar Index, Commodities Rise -- Market Talk

13 jun 2025, 17:02 UTC

Adquisiciones, fusiones, absorciones

Advent Proposal Values Spectris at GBP37.63 Per Share, Company Said Monday -- WSJ

13 jun 2025, 17:02 UTC

Adquisiciones, fusiones, absorciones

KKR Is Preparing a Bid for High-Tech Instrument Maker Spectris, Sources Say -- WSJ

13 jun 2025, 17:02 UTC

Adquisiciones, fusiones, absorciones

Private-Equity Firm Is Vying With Advent for the U.K. Company, Sources Say -- WSJ

13 jun 2025, 17:02 UTC

Adquisiciones, fusiones, absorciones

KKR Making Competing Bid for Equipment Maker Spectris -- WSJ

13 jun 2025, 16:20 UTC

Charlas de Mercado

Auto & Transport Roundup: Market Talk

Comparación entre iguales

Cambio de precio

Arbutus Biopharma Corp previsión

Precio Objetivo

By TipRanks

41.64% repunte

Estimación a 12 Meses

Media 5 USD  41.64%

Máximo 5 USD

Mínimo 5 USD

De acuerdo con 1 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Arbutus Biopharma Corp Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

1 ratings

1

Comprar

0

Mantener

0

Vender

Puntuación técnica

By Trading Central

3.255 / 3.365Soporte y Resistencia

Corto Plazo

Weak Bearish Evidence

Medio plazo

Bullish Evidence

Largo Plazo

Weak Bullish Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Arbutus Biopharma Corp

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.